PMID- 28616427
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2319-9644 (Print)
IS  - 2279-042X (Electronic)
IS  - 2279-042X (Linking)
VI  - 6
IP  - 2
DP  - 2017 Apr-Jun
TI  - Specific Genes Associated with Adverse Events of Methylphenidate Use in the 
      Pediatric Population: A Systematic Literature Review.
PG  - 65-72
LID - 10.4103/jrpp.JRPP_16_161 [doi]
AB  - The aim of this study was to review empirical studies examining associations 
      between candidate genes and adverse events (AEs) from methylphenidate (MPH) use 
      in children and adolescents. The PubMed, EMBASE, CINAHL, and Web of Science 
      databases were searched from their inception until March 2017. We included 
      empirically based articles on pharmacogenetic studies in 0-17-year-old patients 
      that investigated associations between specific candidate genes, their 
      polymorphisms, and reported AEs. We extracted information about study design, 
      setting, type of AE reporter, studied genes and their polymorphisms, age and 
      gender, administered doses, method of genotyping, outcome measures, and main 
      findings. A total of nine articles reporting information about four double-blind, 
      placebo-controlled, cross-over studies and five open-label cohort studies were 
      eligible for inclusion. Studies were published from 2006 onward and included a 
      total of 998 patients (3-17-year-olds) diagnosed with attention-deficit 
      hyperactivity disorder (ADHD). Studies predominantly involved males and lasted 
      from 1 to 12 weeks. Studies used polymerase chain reaction and single nucleotide 
      polymorphism genotyping methodology. Reported AEs were significantly associated 
      with the following genes: appetite reduction (CES1*G); buccal-lingual movements 
      (T1065G); diastolic blood pressure (ADRA2A Mspl C/C-GC); emotionality (DAT1*9/9); 
      irritability (SNAP25 T1065G); picking (DRD4*7/DRD4*4); social withdrawal 
      (DRD4*7/DRD4*4); somatic complaints (DAT1*10/10); tics (5-HTTLRP*S/L*L/L; SNAP25 
      T1065G); sadness (CES1*rsl12443580); and vegetative symptoms (5-HTTLPR). In 
      conclusion, only few MPH pediatric pharmacogenetic studies were located, and 
      large between-study heterogeneity was found. Studies were of naturalistic design 
      and of short duration. They included small patient samples, poorly standardized 
      treatment regimens, and limited outcome assessments. In the future, more 
      pharmacogenomic studies in ADHD are needed, preferably using randomized, 
      controlled study designs and of longer duration (more than 6 months).
FAU - Joensen, Beinta
AU  - Joensen B
AD  - Department of Neurobiology Research, Institute of Molecular Medicine, University 
      of Southern Denmark, Odense, Denmark.
FAU - Meyer, Morten
AU  - Meyer M
AD  - Department of Neurobiology Research, Institute of Molecular Medicine, University 
      of Southern Denmark, Odense, Denmark.
AD  - Department of Neurology, Zealand University Hospital, Roskilde, Denmark.
FAU - Aagaard, Lise
AU  - Aagaard L
AD  - Life Science Team, IP and Technology, Bech-Bruun Law Firm, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - India
TA  - J Res Pharm Pract
JT  - Journal of research in pharmacy practice
JID - 101614023
PMC - PMC5463551
OTO - NOTNLM
OT  - Adverse drug reaction
OT  - Methylphenidate
OT  - adverse event
OT  - attention-deficit hyperactivity disorder
OT  - pediatric
OT  - pharmacogenetics
COIS- There are no conflicts of interest.
EDAT- 2017/06/16 06:00
MHDA- 2017/06/16 06:01
PMCR- 2017/04/01
CRDT- 2017/06/16 06:00
PHST- 2017/06/16 06:00 [entrez]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2017/06/16 06:01 [medline]
PHST- 2017/04/01 00:00 [pmc-release]
AID - JRPP-6-65 [pii]
AID - 10.4103/jrpp.JRPP_16_161 [doi]
PST - ppublish
SO  - J Res Pharm Pract. 2017 Apr-Jun;6(2):65-72. doi: 10.4103/jrpp.JRPP_16_161.